The SLC9A3R1 (solute carrier family 9 member A3 regulator 1) antibody is a tool for studying the NHERF1 protein, a scaffold protein encoded by the SLC9A3R1 gene. NHERF1 contains two PDZ domains and a C-terminal ezrin-binding region, enabling interactions with membrane receptors, ion channels, and cytoskeletal components. It regulates cellular processes like ion transport, signal transduction, and membrane trafficking by organizing multiprotein complexes.
SLC9A3R1 antibodies are widely used in research to detect NHERF1 expression in tissues or cell lines via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help investigate NHERF1's role in modulating signaling pathways (e.g., EGFR, PTEN) and its involvement in diseases, including cancer, kidney disorders, and osteoporosis. For instance, NHERF1 dysregulation is linked to tumor progression through interactions with β-catenin/Wnt or PDZK1 pathways.
Commercially available SLC9A3R1 antibodies are typically raised in rabbits or mice, targeting specific epitopes (e.g., C-terminal regions). Validation data (e.g., knockout controls) are critical to ensure specificity, as cross-reactivity with homologous proteins like NHERF2 may occur. Researchers utilize these antibodies to explore NHERF1's tissue distribution, post-translational modifications, and disease-associated molecular mechanisms, aiding therapeutic target discovery.